Nuvation BioNUVB
About: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Employees: 220
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
78% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 36
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
22% more capital invested
Capital invested by funds: $430M [Q3] → $526M (+$96.3M) [Q4]
3% more funds holding
Funds holding: 154 [Q3] → 159 (+5) [Q4]
2.55% more ownership
Funds ownership: 56.2% [Q3] → 58.75% (+2.55%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]
100% less call options, than puts
Call options by funds: $3K | Put options by funds: $952K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Jones Trading Soumit Roy 19% 1-year accuracy 3 / 16 met price target | 502%upside $10 | Buy Initiated | 12 Mar 2025 |
HC Wainwright & Co. Robert Burns 15% 1-year accuracy 25 / 172 met price target | 502%upside $10 | Buy Maintained | 10 Mar 2025 |
RBC Capital Gregory Renza 27% 1-year accuracy 20 / 74 met price target | 502%upside $10 | Outperform Reiterated | 7 Jan 2025 |
Financial journalist opinion
Based on 4 articles about NUVB published over the past 30 days









